MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.730
+0.290
+8.43%
After Hours: 3.660 -0.07 -1.88% 17:58 07/10 EDT
OPEN
3.450
PREV CLOSE
3.440
HIGH
3.800
LOW
3.400
VOLUME
1.67M
TURNOVER
--
52 WEEK HIGH
15.00
52 WEEK LOW
2.550
MARKET CAP
93.07M
P/E (TTM)
-2.3660
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZYNE stock price target is 9.17 with a high estimate of 12.00 and a low estimate of 4.500.

EPS

ZYNE News

More
Cannabis Stock Gainers And Losers From July 8, 2020
Gainers Green Organic Dutchman (OTC: TGODF) shares closed up 13.03% at $0.31 Bloom Energy (NYSE: BE) shares closed up 10.39% at $12.54
Benzinga · 2d ago
The Week In Cannabis: Stocks Underperform Broader Market, Bad News For Zynerba, Organigram And More
It was a relatively quiet week ahead of the Fourth of July. Nonetheless, a handful of announcements had the cannabis markets buzzing.
Benzinga · 5d ago
The Week In Cannabis: Stocks Underperform Broader Market, Bad News For Zynerba, Organigram And More
It was a relatively quiet week ahead of the Fourth of July. Nonetheless, a handful of announcements had the cannabis markets buzzing.Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) plummeted after the company, focused on the development of cannabinoid-based therapi
Benzinga · 5d ago
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/02 07:14
ESPAÑOL • Zynerba, Tilray, Aurora Cannabis, SPACs, Marihuana en Santa Fe, Cumple Años Elon Musk, y Entrevista con Nikola Motors
Las últimas noticias sobre cannabis, cáñamo, CBD, psicodélicos, y otras temáticas verdes, ahora en Benzinga en Español, vía El Planteo.
Benzinga · 07/01 17:05
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study
Zacks · 07/01 14:36
FDX, BYND among premarket gainers
Seeking Alpha - Article · 07/01 12:11
Needham Downgrades Zynerba Pharmaceuticals to Hold
Needham analyst Serge Belanger downgrades Zynerba Pharmaceuticals (NASDAQ:ZYNE) from Buy to Hold.
Benzinga · 07/01 11:29

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About ZYNE

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
More

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.